Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10–20% of cases are pediatric or adolescent/young adult (AYA) patients. Tagraxofusp (TAG, Elzonris®) is the only approved treatment for BPDCN; in the United States it is approved for patients...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Naveen Pemmaraju, Branko Cuglievan, Joseph Lasky, Albert Kheradpour, Nobuko Hijiya, Anthony S. Stein, Soheil Meshinchi, Craig A. Mullen, Emanuele Angelucci, Luciana Vinti, Tariq I. Mughal, Anna B. Pawlowska
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2024-02-01
Serija:	eJHaem
Teme:	AYA BPDCN CD123 pediatric BPDCN plasmacytoid dendritic cells tagraxofusp
Online dostop:	https://doi.org/10.1002/jha2.856
Oznake:	Označite Brez oznak, prvi označite!